The content on this site is intended for healthcare professionals only
Selumetinib, a small-molecule MEK inhibitor, demonstrated the ability to control low-grade serous ovarian or peritoneal cancer, according to phase II study results presented at a press conference at the AACR Annual Meeting 2012.
ecancerNews Coverage: Selumetinib controlled recurrent low-grade serous ovarian cancer
Choosing Wisely in endometrial & cervix cancers: Medical therapy
Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype
The treatment of cervical cancer in the presence of HIV in Sub-Saharan Africa
Low-dose olanzapine after highly emetogenic chemotherapy can be the new standard of care for solid tumours
First-line chemotherapy with atezolizumab and bevacizumab significantly improves survival for R/M cervical cancer
Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer
OncoAlert round up July 28th to August 3rd, 2023
Gynaecological cancer: New targets and immunotherapy developments
